NCT05089123View on ClinicalTrials.gov

The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

PHASE3CompletedINTERVENTIONAL

Enrollment

320

Participants

Timeline

Start Date

March 3, 2020

Primary Completion Date

May 28, 2020

Study Completion Date

August 24, 2020

Conditions

Influenza

Interventions

BIOLOGICAL

Flu-M [Inactivated split influenza vaccine]

solution for intramuscular injection, 0.5 ml

BIOLOGICAL

Inactivated Split Influenza Vaccine

solution for intramuscular injection, 0.5 ml

Trial Locations (2)

Unknown

"LLC Meditsinskie Tehnologii", Saint Petersburg

"LLC Strategicheskie Meditsinskie Sistemi", Saint Petersburg

All Listed Sponsors

lead

St. Petersburg Research Institute of Vaccines and Sera

OTHER_GOV

NCT05089123 - The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old | Biotech Hunter | Biotech Hunter